Japanese pharma and biotech friend Takeda is set to spend nearly $1 billion in backloaded payments for a deal with early-stage startup Carmine Therapeutics. The pair will target rare diseases using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results